Clinical Trials Logo
  1. Home
  2. Migraine With or Without Aura
  3. NCT01986088

Eletriptan vs Sumatriptan: A Double-blind, Placebo-controlled, Multiple Migraine Attack Study

Migraine With or Without Aura Clinical Trial

Official title:
A Multicentre, Double Blind, Double Dummy, Parallel Group, Placebo Controlled, Study of Two Dose Levels of Oral Eletriptan and Two Dose Levels Oral Sumatriptan Given for the Acute Treatment of Migraine(With and Without Aura).

Clinical Trial Summary

A previously published, placebo-controlled, head-to-head comparator study found eletriptan to have superior efficacy to oral sumatriptan 100 mg in treating a single acute migraine attack. The goal of the current study was to extend the findings of that study by examining the efficacy of eletriptan compared with both 50- and 100-mg doses of sumatriptan; and to evaluate the comparative efficacy of eletriptan and sumatriptan across additional important clinical outcomes. In particular, early response (at 1 hour), sustained response (without need for additional treatment) at 24 hours, and consistency of response across multiple attacks were examined.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01986088
Study type Interventional
Source Pfizer
Contact
Status Completed
Phase Phase 3
Start date November 1996
Completion date January 1998
View Details
See also
  Status Clinical Trial Phase
Completed NCT00792636 - A Study to Determine the Effect of Sumatriptan and Naproxen Sodium Combination Tablet, Sumatriptan Tablet, and Naproxen Sodium Tablet on Blood Pressure When Treating Migraine Headaches That Occur During a 6-month Period Phase 4
Completed NCT00383162 - A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 1 of 2) Phase 3
Completed NCT02605174 - Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine Phase 3
Completed NCT01978496 - Efficacy, Safety, and Tolerability of Oral Eletriptan for Treatment of Acute Migraine Phase 3
Completed NCT01989936 - Eletriptan for the Treatment of Migraine in Patients With Previous Poor Response or Tolerance to Oral Sumatriptan Phase 3
Completed NCT06245902 - An Acute Migraine Factorial Study Phase 2
Completed NCT03061734 - Low-Dose Naltrexone and Acetaminophen Combination and Its Components in the Acute Treatment of Migraine Phase 2
Completed NCT00382993 - A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 2 of 2) Phase 3
Completed NCT01986270 - Comparative Study of Oral Eletriptan (40mg and 80mg), Oral Sumatriptan (25mg and 50mg) and Placebo Phase 3
Completed NCT03194555 - The Preventive Treatment of Migraine With Low-Dose Naltrexone and Acetaminophen Combination Phase 2